https://scholars.lib.ntu.edu.tw/handle/123456789/633530
標題: | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial | 作者: | Hurvitz, Sara A Hegg, Roberto Chung, Wei-Pang Im, Seock-Ah Jacot, William Ganju, Vinod Chiu, Joanne Wing Yan Xu, Binghe Hamilton, Erika Madhusudan, Srinivasan Iwata, Hiroji Altintas, Sevilay Henning, Jan-Willem Curigliano, Giuseppe Perez-Garcia, José Manuel Kim, Sung-Bae Petry, Vanessa CHIUN-SHENG HUANG et al., |
公開日期: | 14-一月-2023 | 卷: | 401 | 期: | 10371 | 來源出版物: | Lancet (London, England) | 摘要: | An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast03 trial. The aim of DESTINY-Breast03 was to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633530 | ISSN: | 01406736 | DOI: | 10.1016/S0140-6736(22)02420-5 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。